← Back to Search

Anti-VEGF Antibody

RBM-007 Injectable Solution for Age-Related Macular Degeneration (TEMPURA Trial)

Phase 1 & 2
Waitlist Available
Research Sponsored by Maturi, Raj K., M.D., P.C.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

TEMPURA Trial Summary

This study is evaluating whether a new drug may help reduce swelling in the eye for individuals with macular degeneration.

Eligible Conditions
  • Age-Related Macular Degeneration

TEMPURA Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Macular Edema
Secondary outcome measures
Visual Acuity

Side effects data

From 2021 Phase 2 trial • 94 Patients • NCT04200248
46%
Eye disorders
18%
Conjunctival haemorrhage
14%
Dry eye
7%
Eye irritation
7%
Eye pain
7%
Iritis
7%
Vitritis
100%
80%
60%
40%
20%
0%
Study treatment Arm
Sham + RBM-007
RBM-007 + Aflibercept
Sham + Aflibercept

TEMPURA Trial Design

1Treatment groups
Experimental Treatment
Group I: RBM-007 Injectable Solution - 2.0 mgExperimental Treatment1 Intervention
Single intravitreal injection in study eye
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
RBM-007 Injectable Solution
2019
Completed Phase 2
~110

Find a Location

Who is running the clinical trial?

Maturi, Raj K., M.D., P.C.Lead Sponsor
6 Previous Clinical Trials
180 Total Patients Enrolled
Raj K. Maturi, M.D.Study ChairMidwest Eye Institute

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration
2021. "RBM-007 in Treatment naïve Exudative Age-related Macular Degeneration". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04895293.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top